Oncocercosis: de lo básico a lo clínico
Barra lateral del artículo
Descargas
Esta obra está bajo una licencia Creative Commons Reconocimiento 3.0 Unported.
Contenido principal del artículo
Resumen
La oncocercosis es una de las enfermedades tropicales desatendidas, producida por el nemátodo filárico Onchocerca volvulus y transmitida por la picadura de la mosca negra del género Simulium. Es considerada la segunda causa mundial de ceguera prevenible y está presente en 35 naciones de tres continentes: África, América y Asia. Existen tres países declarados libres de oncocercosis: Colombia, Ecuador y México. Las principales manifestaciones clínicas son dermatológicas y oculares; sin embargo, también se han descrito alteraciones linfáticas y neurológicas. El diagnóstico se realiza por identificación de microfilarias en biopsia de piel o esclerocorneal, nodulectomía para buscar gusanos adultos o con lámpara de hendidura y observar el parásito en el ojo. Existe tratamiento farmacológico con ivermectina o quirúrgico con extracción directa de los nemátodos adultos de los oncocercomas. Los programas mundiales se basan en control vectorial y farmacoterapia. Con los conocimientos actuales y esfuerzos mundiales, la oncocercosis continúa siendo un grave problema de salud pública y causa de discapacidad. Por estas razones, se hace necesario una actualización en el tema.
Citas
Nelson R. Neglected tropical diseases take hold in the USA. Lancet Infect Dis. 2014; 14(11):1050- 1051.
Organización Mundial de la Salud. Enfermedades tropicales desatendidas: preguntas más frecuentes. [Sitio en internet]. Hallado en: http://www.who.int/topics/tropical_diseases/qa/ faq/es/ Acceso 8 junio de 2015.
Litt E, Baker MC, Molyneux D. Neglected tropical diseases and mental health: A perspective on comorbidity. Trends Parasitol 2012; 28(5):195-201.
World Health Organization. Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers. Geneva; 2006.
World Health Organization. Working to overcome the global impact of neglected tropical diseases. Geneva; 2010.
No authors listed. Working to overcome the global impact of neglected tropical diseases –Summary. Wkly Epidemiol Rec. 2011; 86(13):113-120.
Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859):2197-2223.
Nakagawa J, Ehrenberg JP, Nealon J, Fürst T, Aratchige P, Gonzales G, et al. Towards effective prevention and control of helminth neglected tropical diseases in the Western Pacific Region through multi-disease and multi-sectoral interventions. Acta Trop 2015; 141(Pt B):407-418.
Fenwick A. The global burden of neglected tropical diseases. Public Health 2012; 126(3):233-236.
Centers for Disease Control and Prevention. Parasites - Onchocerciasis (also known as River Blindness). [Sitio en internet]. Hallado en: http://www.cdc.gov/parasites/onchocerciasis/ health_professionals/ Acceso en 27 junio de 2016.
Crump A, Morel CM, Omura S. The onchocerciasis chronicle: from the beginning to the end? Trends Parasitol 2012; 28(7):280-288.
Gustavsen K, Hopkins A, Sauerbrey M. Onchocerciasis in the Americas: from arrival to (near) elimination. Parasit Vectors 2011; 4:205.
Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA. Chapter 46. Medical Parasitology. In: Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA. eds. Jawetz, Melnick, & Adelberg’s Medical Microbiology, 26e. New York, NY: McGraw-Hill; 2013.
World Health Organization. Guidelines for Stopping Mass Drug Administration and Verifying Elimination of Human Onchocerciasis: Criteria and Procedures. Geneva: WHO; 2016.
Dunn C, Callahan K, Katabarwa M, Richards F, Hopkins D, Withers PC Jr, et al. The Contributions of Onchocerciasis Control and Elimination Programs toward the Achievement of the Millennium Development Goals. PLoS Negl Trop Dis 2015; 9(5):e0003703.
Norris J, Adelman C, Spantchak Y, Marano K. Social and Economic Impact Review on Neglected Tropical Diseases. Washington DC: The Hudson Institute; 2012.
Organización Mundial de la Salud. Oncocercosis. [Sitio en internet]. Hallado en: http://www. who.int/mediacentre/factsheets/fs374/es/ Acceso en 23 junio de 2016.
Rodríguez-Pérez MA, Unnasch TR, Real-Najarro O. Assessment and monitoring of onchocerciasis in Latin America. Adv Parasitol 2011; 77:175-226.
Centers for Disease Control and Prevention (CDC). Progress toward elimination of onchocerciasis in the Americas - 1993-2012. MMWR Morb Mortal Wkly Rep 2013; 62(20):405-408.
Coffeng LE, Fobi G, Ozoh G, Bissek AC, Nlatté BO, Enyong P, et al. Concurrence of dermatological and ophthalmological morbidity in onchocerciasis. Trans R Soc Trop Med Hyg 2012; 106(4):243- 251.
Murray CJL, Lopez AD. Progress and directions in refining the global burden of disease approach: A response to Williams. Health Econ 2000; 9:69–82.
Thylefors B, Négrel AD, Pararajasegaram R, Dadzie KY. Global data on blindness. Bull World Health Organ 1995; 73(1):115-121.
Knudson A, Ariza Y, López MC, Fajardo OS, Reyes P, Moncada LI, et al. [The effect of ivermectin on geohelminth frequency (i.e. as used in the onchocerciasis control program in Colombia)]. Rev Salud Pública (Bogotá) 2012; 14(4):681-694.
Rodríguez GC, Lizarazo C. Revisión epidemiológica de la Oncocercosis en América Latina. Rev Fac Nac Salud Pública 2010; 28(1):73-80.
Pérez Cárdenas JE. Razones por las cuales Colombia fue el primer país en lograr la eliminación de la oncocercosis. Biosalud [serial on the Internet]. 2013 June [cited 2015 July 02]; 12(1): 5-7. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S1657- 95502013000100001&lng=en.
Ministerio de Salud y Protección Social, Programa Nacional de Eliminación de la Oncocercosis de Colombia (Pneoc), Instituto Nacional de Salud. Oncocercosis. Bogotá: Minsalud, Pneoc, INS; 2014. Protocolo de Vigilancia en Salud Pública.
Furtado JM, Lansingh VC, Carter MJ, Milanese MF, Peña BN, Ghersi HA, et al. Causes of blindness and visual impairment in Latin America. Surv Ophthalmol 2012; 57(2):149-177.
Hopkins DR. Disease eradication. N Engl J Med 2013; 368(1):54-63.
Organización Mundial de la Salud. Salud ocular universal: un plan de acción mundial para 2014-2019. Ginebra: OMS; 2013.
Organización Mundial de la Salud. Proyecto de plan de acción para la prevención de la ceguera y la discapacidad visual evitables 2014-2019. Salud ocular universal: un plan de acción mundial para 2014-2019. Ginebra: OMS; 2013. Informe de la Secretaría 66º Asamblea Mundial de la Salud.
Keating J, Yukich JO, Mollenkopf S, Tediosi F. Lymphatic filariasis and onchocerciasis prevention, treatment, and control costs across diverse settings: a systematic review. Acta Trop 2014; 135:86-95.
West S, Munoz B, Sommer A. River blindness eliminated in Colombia. Ophthalmic Epidemiol 2013; 20(5):258-259.
Coffeng LE, Stolk WA, Zouré HG, Veerman JL, Agblewonu KB, Murdoch ME, et al. African programme for onchocerciasis control 1995-2015: updated health impact estimates based on new disability weights. PLoS Negl Trop Dis 2014; 8(6):e2759.
No authors listed. Report from the 2009 Inter-American Conference on Onchocerciasis: progress towards eliminating river blindness in the Region of the Americas. Wkly Epidemiol Rec. 2010; 85:321-326.
No authors listed. Progress toward eliminating onchocerciasis in the WHO Region of the Americas: verification of elimination of transmission in Mexico. Wkly Epidemiol Rec. 2015; 90(43):577-581.
Kaiser C, Pion SD, Boussinesq M. Case-control studies on the relationship between onchocerciasis and epilepsy: systematic review and meta-analysis. PLoS Negl Trop Dis 2013; 7(3):e2147.
Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet. 2010; 376(9747):1175-1185.
Rodríguez GC, Lizarazo C. Revisión epidemiológica de la Oncocercosis en América Latina. Rev Fac Nac Salud Pública. [serial on the Internet]. 2010 Jan [cited 2015 July 02]; 28(1): 73-80. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120- 386X2010000100010&lng=en
Capítulo 11 Filariasis. En: Botero D, Restrepo M. 5 eds. Parasitosis humanas incluye animales venenosos y ponzoñosos. Medellín, Antioquia: CIB; 2012. Pp. 413-447.
Kaiser C, Pion S, Boussinesq M. Do helminths cause epilepsy? The case of Onchcerca volvulus. Parasite Immunol. 2010; 32:79–80.
Que SK, Weston G, Suchecki J, Ricketts J. Pigmentary disorders of the eyes and skin. Clin Dermatol. 2015; 33(2):147-158.
West S, Munoz B, Sommer A. River blindness eliminated in Colombia. Ophthalmic Epidemiol 2013; 20(5):258-259.
Enk CD. Onchocerciasis--river blindness. Clin Dermatol. 2006; 24(3):176-180.
Ejere HOD, Schwartz E, Wormald R, Evans JR. Ivermectin for onchocercal eye disease (river blindness). Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No.: CD002219.
Winkler AS, Friedrich K, Velicheti S, Dharsee J, König R, Nassri A, et al. MRI findings in people with epilepsy and nodding syndrome in an area endemic for onchocerciasis: an observational study. Afr Health Sci 2013; 13(2):529-540.
Foltz JL, Makumbi I, Sejvar JJ, Malimbo M, Ndyomugyenyi R, Atai-Omoruto AD, et al. An Epidemiologic Investigation of Potential Risk Factors for Nodding Syndrome in Kitgum District, Uganda. PLoS One 2013; 8(6):e66419.
Colebunders R, Post R, O’Neill S, Haesaert G, Opar B, Lakwo T, et al. Nodding syndrome since 2012: recent progress, challenges and recommendations for future research. Trop Med Int Health 2015; 20(2):194-200.
Colebunders R, Hendy A, Nanyunja M, Wamala JF, van Oijen M. Nodding syndrome-a new hypothesis and new direction for research. Int J Infect Dis 2014; 27:74-77.
Dowell SF, Sejvar JJ, Riek L, Vandemaele KA, Lamunu M, Kuesel AC, et al. Nodding syndrome. Emerg Infect Dis 2013; 19(9):1374-1384.
Sejvar JJ, Kakooza AM, Foltz JL, Makumbi I, Atai-Omoruto AD, Malimbo M, et al. Clinical, neurological, and electrophysiological features of nodding syndrome in Kitgum, Uganda: An observational case series. Lancet Neurol 2013; 12(2):166-174.
VanRooyen MJ, Venugopal R. World Travelers. In: Tintinalli JE, Stapczynski J, Ma O, Cline DM, Cydulka RK, Meckler GD, T. eds. Tintinalli’s Emergency Medicine: A Comprehensive Study Guide, 7e. New York, NY: McGraw-Hill; 2011.
Rosenthal PJ. Protozoal & Helminthic Infections. In: Papadakis MA, McPhee SJ, Rabow MW. eds. Current Medical Diagnosis & Treatment 2015. New York, NY: McGraw-Hill; 2014.
Berkowitz AL, Raibagkar P, Pritt BS, Mateen FJ. Neurologic manifestations of the neglected tropical diseases. J Neurol Sci 2015; 349(1-2):20-32.
Ayong L, Tume C, Wembe F, et al. Development and evaluation of an antigen detection dipstick assay for the detection of human onchocerciasis. Trop Med Int Health 2005; 10:228–233.
Juckett G. Chapter 11. The Neglected Tropical Diseases. In: Markle WH, Fisher MA, Smego RA, Jr. eds. Understanding Global Health, 2e. New York, NY: McGraw-Hill; 2014.
Levinson W. Nematodes. In: Levinson W. eds. Review of Medical Microbiology and Immunology, 13e. New York, NY: McGraw-Hill; 2014.
Nutman TB, Weller PF. Filarial and Related Infections. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. eds. Harrison’s Principles of Internal Medicine, 19e. New York, NY: McGraw-Hill; 2015.
Walker M, Specht S, Churcher TS, Hoerauf A, Taylor MJ, Basáñez MG. Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness. Clin Infect Dis 2015; 60(8):1199-1207.
Moore TA. Agents Used to Treat Parasitic Infections. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. eds. Harrison’s Principles of Internal Medicine, 19e. New York, NY: McGraw-Hill; 2015.
Rosenthal PJ. Clinical Pharmacology of the Antihelminthic Drugs. In: Katzung BG, Trevor AJ. eds. Basic & Clinical Pharmacology, 13e. New York, NY: McGraw-Hill; 2015.
Udall DN. Recent updates on onchocerciasis: diagnosis and treatment. Clin Infect Dis. 2007; 44(1):53-60.
Fobi G, Gardon J, Kamgno J, Aimard-Favennec L, Lafleur C, Gardon-Wendel N, et al. A randomized, double-blind, controlled trial of the effects of ivermectin at normal and high doses, given annually or three-monthly, against Onchocerca volvulus: ophthalmological results. Trans R Soc Trop Med Hyg 2005; 99:279–289.
Kamgno J, Gardon J, Gardon-Wendel N, Demanga-Ngangue, Duke BO, Boussinesq M. Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly. Trans R Soc Trop Med Hyg. 2004; 98:496–504.
McCarthy J, Loukas A, Hotez PJ. Chapter 51. Chemotherapy of Helminth Infections. In: Brunton LL, Chabner BA, Knollmann BC. eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 12e. New York, NY: McGraw-Hill; 2011.
Burki T. River blindness elimination in Columbia. Lancet Infect Dis 2013; 13(11):922-923.
Babalola OE. Ocular onchocerciasis: current management and future prospects. Clin Ophthalmol 2011; 5:1479-1491
Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascendingdose, ivermectin-controlled, double-blind study of moxidectin in: Onchocerca volvulus infection. PLoS Negl Trop Dis 2014; 8(6):e2953.